Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: The role of the fas pathwayin the metastatic process of osteosarcoma

Molecular Cancer Research

Volumn 5, Issue 10, 2007, Pages 991-999

  Koshkina, Nadezhda V ^a   Khanna, Chand ^b   Mendoza, Arnulfo ^b   Guan, Hui ^a   DeLauter, Lindsey ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL SELECTION; CONTROLLED STUDY; GENETIC TRANSFECTION; LUNG METASTASIS; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PLASMID; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD95; BONE NEOPLASMS; CELL LINE, TUMOR; FAS LIGAND PROTEIN; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; LUNG NEOPLASMS; MICE; MICE, MUTANT STRAINS; OSTEOSARCOMA; PLASMIDS; TRANSFECTION;

MUS;

EID: 35948951989     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-0007     Document Type: Article

References (35)

1. Schmidt-Kittler O, Ragg T, Daskalakis A, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A 2003;100:7737-42.
2. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004;9:422-41.
3. Gordon N, Arndt CA, Hawkins DS, et al. Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 2005;27:611-5.
4. Worth LL, Lafleur EA, Jia SF, Kleinerman ES. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 2002;9:823-7.
5. Owen-Schaub LB, van Golen KL, Hill LL, Price JE. Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp Med 1998;188:1717-23.
6. Sayers TJ, Brooks AD, Lee JK, et al. Molecular mechanisms of immunemediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells. J Immunol 1998;161:3957-65.
7. Lee JK, Sayers TJ, Brooks AD, et al. IFN-γ-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells. J Immunol 2000;164:231-9.
8. Koshkina NV, Kleinerman ES. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer 2005;116:458-63.
9. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
10. French LE, Hahne M, Viard I, et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996;133:335-43.
11. Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-56.
12. Gerstenfeld LC, Uporova T, Schmidt J, et al. Osteogenic potential of murine osteosarcoma cells: comparison of bone-specific gene expression in in vitro and in vivo conditions. Lab Invest 1996;74:895-906.
13. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004;10:182-6.
14. Wang WS, Chen PM, Wang HS, Liang WY, Su Y. Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis 2006;27:1113-20.
15. Chan KW, Lee PY, Lam AK, Law S, Wong J, Srivastava G. Clinical relevance of Fas expression in esophageal squamous cell carcinoma. J Clin Pathol 2006;59:101-4.
16. Rodriguez-Pinilla M, Rodriguez-Peralto JL, Hitt R, et al. β-Catenin, NF-κB and FAS protein expression are independent events in head and neck cancer: study of their association with clinical parameters. Cancer Lett 2005;230:141-8.
17. Volm M, Koomagi R. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival. Br J Cancer 2000;82:1747-54.
18. Grassme H, Kirschnek S, Riethmueller J, et al. CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science 2000;290:527-30.
19. Kaplan HJ, Leibole MA, Tezel T, Ferguson TA. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat Med 1999;5:292-7.
20. Sabelko-Downes KA, Cross AH, Russell JH. Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. J Exp Med 1999;189:1195-205.
21. Liu K, Abrams SI. Alterations in Fas expression are characteristic of, but not solely responsible for, enhanced metastatic competence. J Immunol 2003;170:5973-80.
22. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002;168:1356-61.
23. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228-37.
24. Asai T, Ueda T, Itoh K, et al. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer 1998;76:418-22.
25. Schroter M, Peli J, Hahne M, Tschopp J, Reichmann E. Fas-dependent tissue turnover is implicated in tumor cell clearance. Oncogene 2000;19:1794-800.
26. Hall CL, Yao M, Hill LL, Owen-Schaub LB. Essential role for hematopoietic Fas ligand (FasL) in the suppression of melanoma lung metastasis revealed in bone marrow chimeric mice. Clin Exp Metastasis 2004;21:251-6.
27. Liu K, McDuffie E, Abrams SI. Exposure of human primary colon carcinoma cells to anti-Fas interactions influences the emergence of pre-existing Fas-resistant metastatic subpopulations. J Immunol 2003;171:4164-74.
28. Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 2004;23:3175-85.
29. Lee JK, Sayers TJ, Back TC, Wigginton JM, Wiltrout RH. Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer. Apoptosis 2003;8:151-60.
30. Peter ME, Legembre P, Barnhart BC. Does CD95 have tumor promoting activities? Biochim Biophys Acta 2005;1755:25-36.
31. Ivanova ST, Dazri AW, Peck D. The Fas/FasL system potentiates invasive phenotype via transcription factor dependent upregulation of metalloproteases [abstract 3453]. Proceedings of the 97th American Association for Cancer Research Annual Meeting 2006.
32. Mitsiades CS, Poulaki V, Fanourakis G, et al. Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin Cancer Res 2006;12:3705-12.
33. Kataoka T, Budd RC, Holler N, et al. The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways. Curr Biol 2000;10:640-8.
34. Chaudhary PM, Eby MT, Jasmin A, Kumar A, Liu L, Hood L. Activation of the NF-nB pathway by caspase 8 and its homologs. Oncogene 2000;19:4451-60.
35. Zhang J, Winoto A. A mouse Fas-associated protein with homology to the human Mort1/FADD protein is essential for Fas-induced apoptosis. Mol Cell Biol 1996;16:2756-63.